Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivosidenib - Servier

Drug Profile

Ivosidenib - Servier

Alternative Names: Tuoshuvo; AG-120; CS 3010; ivonib tablet; S-95031; TIBSOVO; Tosuvo; Tuoshuwo

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Bristol-Myers Squibb; CStone Pharmaceuticals; HOVON Foundation; Servier; University of Pittsburgh Medical Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Glioma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Cholangiocarcinoma; Myelodysplastic syndromes
  • Phase II Glioma; Solid tumours

Most Recent Events

  • 04 Jan 2024 Institut de Recherches Internationales Servier completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US and France (NCT02073994)
  • 21 Dec 2023 Servier acquires Ivosidenib from CStone Pharmaceuticals in China, Hong Kong, Macau, Taiwan and Singapore
  • 21 Dec 2023 Ivosidenib is no longer licensed to CStone Pharmaceuticals in China, Hong Kong, Macau, Taiwan and Singapore
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top